Pancreatic cancer is an aggressive cancer with a low survival time.
So far, there have been no studies assessing direct and indirect costs in individual patients.
Dr Müller-Nordhorn and colleagues assessed prospectively the cost of illness in patients with pancreatic cancer.
The investigators reported that patients were consecutively included at first admission to hospital.
Sociodemographic factors, medical resource use and employment status were assessed by patient interviews and from medical records in a standardized way.
The team calculated costs from the perspectives of the hospital, social insurance and society.
|Total costs were 4075,- and 75% of this was due to hospitalizations|
|Alimentary Pharmacology & Therapeutics|
Linear regression analyses were used by the investigators to determine factors associated with costs.
A total of 57 patients were admitted with suspected pancreatic cancer.
Of these patients, the investigators found that 45 had pancreatic cancer as final diagnosis, 11 had pancreatitis and 1 patient cystadenoma.
The team observed that median survival was 11 months in patients with pancreatic cancer.
Per month of observation from societal perspective, the investigators noted that total costs were 4075,- for patients.
The investigative team found that costs of hospitalizations were responsible for 75% of total costs.
In multivariable analyses, surgery, a lower educational level, younger age, and the prevalence of metastases were significantly associated with higher total costs.
Dr Müller-Nordhorn's team commented, “Costs are considerable in patients with pancreatic cancer.”
“Our results may facilitate further economic evaluations and aid health policy-makers in resource allocation.”